Yu Feng

US Patent:

7151087, Dec 19, 2006

Filed:

Oct 31, 2003

Appl. No.:

10/700313

Inventors:

Christophe Combadiere - Paris, FR
Yu Feng - San Diego CA, US
Ghalib Alkhatib - Carmel IN, US
Edward A. Berger - Rockville MD, US
Philip M. Murphy - Rockville MD, US
Christopher C. Broder - Rockville MD, US
Paul E. Kennedy - Silver Spring MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Resources - Washington DC

International Classification:

A61K 38/00

US Classification:

514 13, 514 14

Abstract:

The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.

US Patent:

20030039955, Feb 27, 2003

Filed:

May 10, 2001

Appl. No.:

09/853745

Inventors:

Yu Feng - San Diego CA, US
Hengli Tang - Carlsbad CA, US

International Classification:

C12N007/00
C07H021/04
C12N015/86
C12N015/867
C12N015/863
C12Q001/70
C12N007/01
C12N015/00
C12N015/09
C12N015/63
C12N015/70
C12N015/74

US Classification:

435/005000, 435/235100, 435/320100, 435/456000, 536/023720

Abstract:

The invention provides methods to produce RNA viral sequences, recombinant RNA viruses, mutants of RNA viruses and RNA virus-derived vectors in cell culture and in vitro using non-viable, replication defective, helper vaccinia recombinants. These methods allow generation of RNA virus sequences and viral particles in cell culture and in vitro independent of their natural replication pathways, bypassing the limitation of any cellular barriers. The invention also provides novel RNA viral sequences and viral particles using these methods.

US Patent:

20030195348, Oct 16, 2003

Filed:

May 15, 2003

Appl. No.:

10/439845

Inventors:

Christophe Combadiere - Rockville MD, US
Yu Feng - San Diego CA, US
Ghalib Alkhatib - Bethesda MD, US
Edward Berger - Rockville MD, US
Philip Murphy - Rockville MD, US
Christopher Broder - Rockville MD, US
Paul Kennedy - Silver Spring MD, US

International Classification:

C07H021/04
C07K014/715
C12P021/02
C12N005/06
A61K038/16

US Classification:

536/023500, 530/350000, 514/012000, 435/069100, 435/320100, 435/325000

Abstract:

The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.

US Patent:

20050064390, Mar 24, 2005

Filed:

Aug 11, 2003

Appl. No.:

10/638797

Inventors:

Edward Berger - Rockville MD, US
Yu Feng - San Diego CA, US
Paul Kennedy - Silver Spring MD, US
Christopher Broder - Rockville MD, US

International Classification:

C12Q001/70
C07H021/04
C07K014/74
C07K014/16
C07K016/28
C12N005/08

US Classification:

435005000, 435069100, 435320100, 435325000, 435366000, 530350000, 530388220, 536023500

Abstract:

The susceptibility to human immunodeficiency virus (HIV) infection depends on the cell surface expression of the human CD4 molecule and a human fusion accessory factor associated with HIV infection (CXCR4). CXCR4 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CXCR4 plays an essential role in the membrane fusion step of HIV infection. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CXCR4 provides valuable tools for the continuing research of HIV infection and the development of more effective anti-HIV therapeutics. In addition, antibodies against CXCR4, isolated and purified peptide fragments of CXCR4, and CXCR4-binding biologic agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics.

US Patent:

20070087990, Apr 19, 2007

Filed:

Nov 7, 2006

Appl. No.:

11/594375

Inventors:

Christophe Combadiere - Paris, FR
Yu Feng - San Diego CA, US
Ghalib Alkhatib - Carmel IN, US
Edward Berger - Rockville MD, US
Philip Murphy - Rockville MD, US
Christopher Broder - Rockville MD, US
Paul Kennedy - Silver Spring MD, US

International Classification:

A61K 31/70
C12P 21/06
A01N 43/04

US Classification:

514044000, 435069100

Abstract:

The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.

US Patent:

20080241167, Oct 2, 2008

Filed:

Mar 7, 2008

Appl. No.:

12/044845

Inventors:

Christophe Combadiere - Paris, FR
Yu Feng - San Diego CA, US
Ghalib Alkhatib - Carmel IN, US
Edward A. Berger - Rockville MD, US
Philip M. Murphy - Rockville MD, US
Christopher C. Broder - Rockville MD, US
Paul E. Kennedy - Silver Spring MD, US

International Classification:

A61K 39/395
C12N 5/06
G01N 33/566
G01N 33/53
C12Q 1/70
C12Q 1/02
A61K 31/7052
C12N 15/87
A61P 31/18

US Classification:

4241721, 435375, 436501, 435 72, 435 5, 435 29, 514 44, 435440

Abstract:

The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.

US Patent:

61975788, Mar 6, 2001

Filed:

Jan 30, 1997

Appl. No.:

8/791388

Inventors:

Edward Berger - Rockville MD
Yu Feng - San Diego CA
Paul Kennedy - Silver Spring MD
Christopher Broder - Rockville MD

Assignee:

The United States of America as represented by the Department of Health and
Human Services - Washington DC

International Classification:

C12N 1500
C12N 1563
C12N 1509
C12N 500

US Classification:

435325

Abstract:

The susceptibility to human immunodeficiency virus (HIV) infection depends on the cell surface expression of the human CD4 molecule and a human fusion accessory factor associated with HIV infection (CXCR4). CXCR4 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CXCR4 plays an essential role in the membrane fusion step of HIV infection. The establishment of stable cell lines that coexpress human CD4 and CXCR4 provides valuable tools for the continuing research of HIV infection and the development of more effective anti-HIV therapeutics.

US Patent:

59395389, Aug 17, 1999

Filed:

Dec 19, 1996

Appl. No.:

8/770235

Inventors:

Markley C. Leavitt - La Jolla CA
Richard Tritz - San Diego CA
Yu Feng - San Diego CA
Jack Barber - San Diego CA
Mang Yu - San Diego CA

Assignee:

Immusol Incorporated - San Diego CA

International Classification:

C07H 2102

US Classification:

536 231

Abstract:

Methods of inhibiting HIV infection by blocking HIV co-receptor RNA expression are provided. Ribozymes which cleave HIV co-receptor RNA and inhibit HIV infection of cells are also provided. Co-receptor targets include fusin and CKR5.